The cancer stem cell (CSC) model depicts that tumors are hierarchically organized and maintained by CSCs lying at the apex. CSCs have been ''identified'' in a variety of tumors through the tumor-forming assay, in which tumor cells distinguished by a certain cell surface marker (known as a CSC marker) were separately transplanted into immunodeficient mice. In such assays, tumor cells positive but not negative for the CSC marker (hereby defined as CSC + and CSC 2 cells, respectively) have the ability of tumor-forming and generating both progenies. However, here we show that CSC + and CSC 2 cells exhibit similar proliferation in the native states. Using a cell tracing method, we demonstrate that CSC 2 cells exhibit similar tumorigenesis and proliferation as CSC + cells when they were co-transplanted into immunodeficient mice. Through serial single-cell derived subline construction, we further demonstrated that CSC + and CSC 2 cells from CSC marker expressing tumors could invariably generate both progenies, and their characteristics are maintained among different generations irrespective of the origins (CSC + -derived or CSC 2 -derived). These findings demonstrate that tumorigenic cells cannot be distinguished by common CSC markers alone and we propose that cautions should be taken when using these markers independently to identify cancer stem cells due to the phenotypic plasticity of tumor cells.
Introduction
A fundamental question in the field of tumor research is which cells can initiate tumors. Two models have been put forward to explain the initiation of tumors [1, 2] . The clonal evolution model (also known as the stochastic model) implies that tumors comprise cells with equal tumorigenic potential and that any functional heterogeneity is attributable to random or stochastic influences (intrinsic or extrinsic) that may alter the behavior of individual cells in the tumor. By contrast, the cancer stem cell (CSC) model (also known as the hierarchy model) argues that, like normal tissues, which are cellular hierarchies maintained by stem cells, tumors can be explained by hierarchical organizations, in which CSCs lying at the apex hold the capacity for tumor initiation, selfrenewal, and generation of phenotypically diverse cells with no or limited proliferative capacity. Advocates of the CSC model propose that CSCs may account for tumor behaviors such as metastasis [3, 4] and resistance to chemotherapy or radiotherapy [5] [6] [7] [8] [9] . Hence, CSC-targeted therapy may be the future direction of tumor treatment [10] [11] [12] [13] .
Through tumor-forming assay in which phenotypically diverse cells were separately transplanted into immunodeficient mice, CSC was first ''identified'' in human acute myeloid leukemia (AML) since only CD34 + CD38 2 cells were found to have the ability of tumor initiation, self-renewal, and generating cells of other subsets under such condition [14] . Since then, the xenotransplantation experimental model has been widely used in CSC studies. Using various cell surface markers, a large body of literature has been published suggesting the existence of CSCs in a variety of tumors such as chronic myeloid leukemia (CML) [15, 16] , acute promyelocytic leukemia (APL) [17, 18] , breast cancer [19] , glioblastoma [20] [21] [22] [23] , colon cancer [24] [25] [26] and melanoma [27] [28] [29] [30] .
However, there is unsettled controversy as to whether the tumor-forming capacity of human tumor cells was correctly reflected in previous studies [31, 32] . Since the efficiency of xenotransplantation in the majority of cases is considerably lower than that for syngeneic transplants, Kelly et al. suggested that the tumor-forming capacity of human tumor cells might be seriously compromised in the mouse milieu due to species-specific differences in the affinity (or recognition) of cytokine and growth factor receptors for their cognate ligands [33] . Besides, Quintana et al. employed a more highly immunocompromised mouse strain (NOD/SCID interleukin-2 receptor gamma chain null [ll2rg2/ 2]) for xenotransplantation assay and found that this could dramatically increase the detectable frequency of cells with tumorigenic potential in human melanoma, suggesting that the tumor-forming capacity of human tumor cells could be greatly compromised due to immune influence in the foreign milieu [34] . These led us to question whether the proliferative and tumorigenic capacity of human tumor cells, especially that of the ''non-CSCs'' could have been underestimated in the previous studies.
In the present study, we evaluated the proliferation and apoptosis of the putative CSCs (CSC + cells) and non-CSCs (CSC 2 cells) in primary tumors as well as tumor cell lines by flow cytometry. In contrast to the previous reports from conventional xenotransplantation assays (transplanting CSC + and CSC 2 cells separately), where CSC 2 cells were shown to have no or limited proliferative capacity [1, 35, 36] , we found no significant differences in proliferation and apoptosis between the two subsets in the native state. We further employed a cell tracing technique to follow the proliferation, tumorigenicity of CSC + and CSC 2 cells. We chose to study cells from several tumor cell lines instead of primary tumors, which might comprise genetically diverse cells [27, 37] 
Results

Expression of CSC markers varies enormously in human primary tumors and tumor cell lines
Previous studies suggested that leukemogenic/tumorigenic cells were restricted to a rare population of tumor cells expressing certain CSC markers [35, 36] . Using a trypsin-free dissociation protocol (to maintain epitope integrity), we detected the percentage of CSC marker positive cells (e.g., CD34
+ CD38 2 for AML, APL, and CML, CD44 +
CD24
2 for breast cancer, CD133 + for glioblastoma and colon cancer, and CD271 + for melanoma) in human primary tumors as well as tumor cell lines by flow cytometric analysis. We found that a considerable number of primary tumors or tumor cell lines do not express those CSC markers ( Figure 1A) , which is consistent with some other reports [38, 39] . In addition, we performed quantitative RT-PCR and found that cells (both CSC + and CSC 2 ) from CSC marker expressing tumors, but not cells from CSC marker non-expressing tumors, express CSC marker mRNA (Figures 1B-F and Figure S1 ), suggesting that the CSC marker expressing and nonexpressing tumors might originate from different types of tumor cells. In primary tumors and tumor cell lines expressing those CSC markers, the percentage of CSC marker positive cells varied enormously, ranging from 0.4% in an AML to as high as 82.7% in a colon cancer ( Figure 1A ). Figure 4 and Figure S2 , both CSC + and CSC 2 cells were capable of generating single cell-derived sublines and giving rise to the two subsets. Initially, the percentage of CSC marker positive cells in single CSC 2 -derived sublines was significantly lower than in single CSC + -derived sublines. However, over an extended period of We carried the single-cell derived subline construction down to the third generation ( Figure 5A) 
CSC
Discussion
The question of which tumor cells contribute to tumor progression has fundamental implications for therapy. Based mainly on the findings that only tumor cells expressing certain cell surface markers could initiate tumor growth when transplanted into immunodeficient mice, advocates of the CSC model propose that tumors are hierarchically organized and hence tumor therapy should be directed at eliminating the tumorigenic cells (i.e., CSCs) [2, 41, 42] . However, here we show that previously identified CSC markers (e.g., CD34
+ CD38 2 for AML, APL, and CML, CD44 + CD24 2 for breast cancer, CD133 + for glioblastoma and colon cancer, CD271
+ for melanoma) do not necessarily filter out tumorigenic cells in these tumors, because both CSC + and CSC 2 cells can initiate tumor growth and give rise to both progenies (ie, CSC + and CSC 2 cells). Our data raise interesting questions regarding the plasticity of tumor hierarchy.
The CSC model posits that the initiation of tumor formation is driven by CSCs while the non-CSCs, which compose the bulk of cells in a tumor, have no or limited capacity for initiation of tumor formation [1, 35, 36] . On the other hand, CSCs were reported to be more quiescent than non-CSCs [41, 43] . If fundamental differences in the proliferative potential does exist between CSCs and non-CSCs, such differences should be easily detected by immunohistochemical or flow cytometric analysis of cell proliferation. However, here we showed that the proliferation and apoptosis of the putative CSCs (CSC + cells) and non-CSCs (CSC 2 cells) were remarkably similar in primary tumors and tumor cell lines, suggesting that the proliferative capacity of CSC 2 cells might have been seriously underestimated in previous studies in which CSC + and CSC 2 cells were separately transplanted into the animals. Therefore, we established a cell tracing method designed to simulate the in situ environment where CSC + and CSC 2 cells coexist. In contrast to the previous reports that CSC 2 cells had no or limited ability of proliferation and hence did not initiate tumor growth [35, 36] , we showed that CSC 2 cells exhibited similar proliferation or sustainability as CSC + cells when both subsets were co-cultured in vitro or co-transplanted into the animals according to their original ratios. These data strongly suggest that, in addition to CSC + cells, CSC 2 cells also are capable of proliferation and tumorigenesis.
The CSC model depicts a tumor as a cellular hierarchy in which only CSCs lying at the apex have the ability of self-renewal and generating cells of the rest. Available evidence supporting the CSC model mostly comes from tumor-forming studies. As mentioned earlier, the tumor-forming assay may not be sufficient to demonstrate a hierarchal organization since the tumor-forming capacity of tumor cells could be dramatically influenced by the intrinsic and extrinsic factors [33, 34] , especially when different subsets of tumor cells are studied separately in a foreign milieu. On the other hand, although some studies showed that CSC
(CD133
2 ) cells in glioblastoma [38] and colon cancer [39] could initiate tumor growth, whether or not there is a CSC marker based hierarchy in these tumors were not investigated extensively. In the present study, we investigated the fate of the cells derived from putative CSCs (CSC + cells) and non-CSCs (CSC 2 cells) by cell tracing under condition where the two subsets coexisted. We found both CSC + and CSC 2 cells could be detected in progenies derived from CSC + (or CSC 2 ) cells both in vitro and in vivo. 2 -derived). These data provide strong evidences that there is no common CSC marker based hierarchy in these tumors.
Cell surface markers have been widely used to distinguish CSCs from non-CSCs and most of the previous studies suggested that CSCs were restricted to a rare population of tumor cells [35, 36] . However, our data suggest that the expression of cell surface markers is more complex than previously recognized. Consistent with some other reports [38, 39] , we showed by flow cytometric analysis that the percentage of CSC marker positive cells varied enormously (ranging from 0.4% in an AML to as high as 82.7% in a colon cancer) in CSC marker expressing tumors and that a considerable number of primary tumors or tumor cell lines did not express those CSC markers. Through quantitative RT-PCR, we further revealed that cells (both CSC + and CSC 2 ) from CSC marker expressing tumors but not cells from CSC marker nonexpressing tumors expressed CSC marker mRNA, suggesting that the CSC marker expressing and non-expressing tumors might originate from different types of tumor cells. Notably, in contrast to both the CSC model and clonal evolution model, in which the phenotypic heterogeneity is attributed to epigenetic and genetic changes, respectively, we show that the expression of CSC markers in cells from CSC marker expressing tumor cell lines can be dynamic. Such phenomenon was also noted by others in some human primary tumors [44] [45] [46] and tumor cell lines [45, 46] . Whether such phenomenon exists in other primary tumors warrants further investigation.
The present data show that both CSC + and CSC 2 cells have the ability of tumorigenesis and that the expression of CSC markers is reversible. However, we do not rule out functional heterogeneity between the two subsets as CSC + cells exhibited higher tumorigenicity than CSC 2 cells when they were transplanted separately into mice. Previously, CSC + cells were reported to exhibit greater immune tolerance (e.g., CD271
+ human melanoma cells [29] ) and higher secretion of growth factors (e.g., CD133
+ human glioblastoma cells [47] ) than CSC 2 cells. Hence, the higher tumorigenicity of CSC + cells in xenotransplantation may either be due to their better adaptation to the foreign milieu and/or their ability to secrete growth factors that are critical for cell survival and proliferation. Whether the CSC + and CSC 2 cells may show overt differences in tumor initiation, metastasis, and resistance to chemotherapy or radiotherapy in the human milieu remains to be further investigated. A better understanding of the underlying mechanisms of the functional heterogeneity might provide important clues for the development and evaluation of novel anticancer therapies.
Conclusions
The present investigation shows the limitation of using common CSC markers to identify a cell population (ie, CSCs) that are exclusively capable of proliferating and initiating tumor growth in the tumor cell lines we studied. Our data are more supportive of the clonal evolution model in which most of the tumor cells are capable of proliferation and tumorigenesis and the functional heterogeneity of tumor cells is attributable to random or stochastic influences (intrinsic or extrinsic). This conclusion is based on the findings that coexisting putative CSCs (CSC + cells) and non-CSCs (CSC 2 cells) exhibited similar capacity for proliferation and tumorigenesis and that both subsets could give rise to CSC + and CSC 2 progenies. Our results suggest the limitations of using these markers independently to differentiate cancer stem cells from non-tumorigenic cells due to the phenotypic plasticity of tumor cells.
Materials and Methods
Ethics statement
Human tumor specimens were obtained from patients after they signed a consent form written in Chinese, which according to 
Tumor cell preparation
Human tumor specimens were obtained from consenting patients according to a protocol approved by the Medical Ethics Committee of Changhai Hospital. Fresh leukemia (AML, APL, and CML) peripheral blood cells were enriched by Ficoll-density gradient centrifugation and washed in Iscove's modified Dulbecco's medium (IMDM) containing 5% fetal calf serum. Solid primary tumor samples (breast cancer, glioblastoma, colon cancer, and melanoma) or xenografts were mechanically dissociated and then digested in a trypsin-free (to maintain epitope integrity) medium containing 150 mg/mL Collagenase Type IV, 2 mg/mL DNase type I and 10 mg/mL hyaluronidase type V (Sigma) for 2 hr at 37uC. The resulting cell suspension was filtered through a 38-mm nylon mesh and single cells were harvested.
Cell labeling
Cells from tumor cell lines were infected with 1 mL of EGFP or DsRed recombinant lentiviral supernatant containing 8 mg/mL polybrene (Invitrogen) with a multiplicity of infection of 1:5 for 2 h at 37uC. Transgenic cells that stably expressed EGFP or DsRed were isolated to construct EGFP-(or DsRed-) labeled cell sublines.
Flow cytometric analysis and cell sorting
After washing with PBS (100 mM, pH 7.2), cells were resuspended in 500 mL Buffer1 (100 mM PBS containing 0.5% BSA). Unlabeled or EGFP-labeled cells from solid tumors were incubated for 1 hour at 4uC with PE-conjugated antibody specific to the CSC markers (CD133 for glioblastoma and colon cancer, CD271 for melanoma) or PE-conjugated mouse IgG1 isotype control antibody (Miltenyi), while DsRed-labeled cells were incubated with FITC-conjugated antibodies. Cells were washed twice, re-suspended in 500 mL Buffer1, and then analyzed or isolated on a MoFlo cell sorter (Dako, with the gate set on the basis of isotype control staining profiles). In the case of leukemia (AML, APL, and CML), unlabeled or GFP-labeled cells were double stained with PE-conjugated mouse anti-human CD34 (BD Biosciences) and APC-conjugated mouse anti-human CD38 antibody (BD Biosciences), while DeRed-labeled cells were double stained with FITC-conjugated mouse anti-human CD34 (BD Biosciences) and APC-conjugated mouse anti-human CD38 antibody. For breast cancer, unlabeled or GFP-labeled cells were double stained with PE-conjugated mouse anti-human CD44 (BD Biosciences) and APC-conjugated mouse anti-human CD24 antibody (BD Biosciences), while DeRed-labeled cells were double stained with FITC-conjugated mouse anti-human CD44 (BD Biosciences) and APC-conjugated mouse anti-human CD24 antibody. Then, different cell subsets were analyzed or isolated on a MoFlo cell sorter as described above. 6 ), which was arbitrarily classified as passage 1 (P1). Then, cells were passaged using a 1:3 dilution and grown to confluency (P2). We repeated this procedure until passage 20. The ratio of DsRed:EGFP cells in different passages was determined by flow cytometry. 
Transplantation of tumor cells
Single-cell derived subline construction
Single CSC + or CSC 2 cell from the CSC marker expressing tumor cell lines were seeded into the 96-well plates. Single-cell derived clones were cultured in the 12-well plates (one clone per well) until confluent (approximately 1610 6 ), which was arbitrarily classified as P1. Then, cells were passaged using a 1:3 dilution and grown to confluency (P2). We repeated this procedure until passage 20.
Statistical analysis
Data are presented as mean 6 SEM. Statistical significance was tested using SPSS15.0 software, with t-tests for 2-group comparisons or analysis of variance (ANOVA) for multiple group comparisons. Tumorigenic difference between CSC + and CSC 2 cells from the same tumor cell lines was tested using Extreme Limiting Dilution Analysis software (available from the Bioinformatics section of the Walter and Eliza Hall Institute of Medical Research, http://bioinf. wehi.edu.au/software/elda/index.html) [48] . 
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